M1 IMMUNODIAGNOSTIC REAGENTS TO DETECT ANTIBODIES AGAINST SARS-COV-2

| Written by Kevin Facun

INVENTORS:

Dr. Salvador Eugenio C. Caoili, Dr. Ruby Anne N. King, Dr. Fresthel Monica M. Climacosa

 

DESCRIPTION

The invention provides peptide-based antigenic constructs comprising a plurality of monomeric units and recognized by immunoglobulins that bind to protein epitopes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); methods for producing said constructs using peptide precursors that comprise artificial sequences, said monomeric units being derived from said precursors; methods and testing systems for detecting said immunoglobulins; and use of said constructs in processes for detecting and producing said immunoglobulins.

 

VALUE PROPOSITION

  • New materials for diagnostics
  • Detection of antibodies against SARS-CoV-2
  • Low-cost antibody test kit

 

MARKET APPLICATIONS AND COMMERCIAL OPPORTUNITIES

In 2020, SARS-CoV-2 was declared by the World Health Organization as a global pandemic. Numerous kits have been commercialized in the market as rapid diagnostic tests (RDTs) and other systems for the detection of SARS-CoV-2 antigens and anti-SARS-CoV-2 antibodies. This technology aims to enable the development of such systems using low-cost materials to be manufactured in the Philippines and elsewhere.

The technology presented can be utilized in R&D and clinical/molecular diagnostic laboratories.

 

DEVELOPMENT STATUS

The technology is currently under further research and development.

 

IP STATUS

  • Patent Application Filed  (Application No. 1-2020-050482)
  • Patent Cooperation Treaty Application Filed

 

TYPE OF PARTNERSHIP BEING SOUGHT

Licensing. Looking for partners or collaborators for clinical validation trials, licensees.